|
WO2020221792A1
|
|
Means and methods of treating burkitt lymphoma or leukemia
|
|
TW202019477A
|
|
Dosing regimen for bcmaxcd3 antibody constructs
|
|
TW201900209A
|
|
Low pH pharmaceutical composition comprising a T cell conjugated antibody construct
|
|
TN2018000266A1
|
|
Psma and cd3 bispecific t cell engaging antibody constructs.
|
|
MX2018009108A
|
|
BCMA and CD3 Bispecific T Cell Engaging Antibody Constructs.
|
|
IL247297D0
|
|
Pharmaceutical compositions with resistance to soluble cea
|
|
JO3620B1
|
|
Immune-checkpoint inhibitors for use in the treatment of blood-borne cancers cancers
|
|
AU2016250023A1
|
|
Bispecific antibody constructs for CDH3 and CD3
|
|
EP3174901A1
|
|
Optimized cross-species specific bispecific single chain antibody constructs
|
|
TW201609811A
|
|
Bispecific single chain antibody construct with enhanced tissue distribution
|
|
EP3531133A1
|
|
Risk-stratification of b-precursor acute lymphoblastic leukemia patients
|
|
AU2014201850A1
|
|
Cross-species-specific PSMAxCD3 Bispecific Single Chain Antibody
|
|
EP3653642A1
|
|
Single chain binding molecules comprising n-terminal abp
|
|
EP2970446A1
|
|
Antibody constructs for influenza m2 and cd3
|
|
JO3529B1
|
|
Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domains
|
|
TW201438735A
|
|
Liquid formulation comprising gm-csf neutralizing compound
|
|
AU2013202375A1
|
|
Means and Methods for the Treatment of Tumorous Diseases
|
|
MX2014010338A
|
|
Long life polypeptide binding molecules.
|
|
AU2012350429A1
|
|
Prevention of adverse effects caused by EpCAMxCD3 bispecific antibodies
|
|
CA2846432A1
|
|
Bispecific binding molecules for 5t4 and cd3
|
